(Q47827786)

6 February 2018

title

The role of hormonal therapy in prostate brachytherapy. Counterpoint. (English)

1 reference

6 February 2018

1 reference

Gregory S Merrick

1

1 reference

6 February 2018

publication date

1 January 2003

1 reference

6 February 2018

published in

Brachytherapy

1 reference

6 February 2018

volume

2

1 reference

6 February 2018

issue

1

1 reference

6 February 2018

page(s)

2-4

1 reference

6 February 2018

Palladium-103 brachytherapy for prostate carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

A dose-response study for I-125 prostate implants

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

High-grade carcinoma of the prostate: a comparison of current local therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

The dosimetry of prostate brachytherapy-induced urethral strictures

1 reference

https://api.crossref.org/works/10.1016%2FS1538-4721%2803%2900010-2

7 January 2021

10.1016/S1538-4721(03)00010-2

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018